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Abstract: The B-vitamins comprise a group of eight water soluble vitamins that perform essential,
closely inter-related roles in cellular functioning, acting as co-enzymes in a vast array of catabolic
and anabolic enzymatic reactions. Their collective effects are particularly prevalent to numerous
aspects of brain function, including energy production, DNA/RNA synthesis/repair, genomic and
non-genomic methylation, and the synthesis of numerous neurochemicals and signaling molecules.
However, human epidemiological and controlled trial investigations, and the resultant scientific
commentary, have focused almost exclusively on the small sub-set of vitamins (B9/B12/B6) that are
the most prominent (but not the exclusive) B-vitamins involved in homocysteine metabolism. Scant
regard has been paid to the other B vitamins. This review describes the closely inter-related functions
of the eight B-vitamins and marshals evidence suggesting that adequate levels of all members of
this group of micronutrients are essential for optimal physiological and neurological functioning.
Furthermore, evidence from human research clearly shows both that a significant proportion of
the populations of developed countries suffer from deficiencies or insufficiencies in one or more
of this group of vitamins, and that, in the absence of an optimal diet, administration of the entire
B-vitamin group, rather than a small sub-set, at doses greatly in excess of the current governmental
recommendations, would be a rational approach for preserving brain health.
Keywords: brain; coenzyme; vitamin; homocysteine; folate; thiamin; niacin; riboflavin; biotin;
pantothenic acid
1. Background
Surprisingly, given their pivotal physiological significance, our understanding of the role of the
B group of vitamins (thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), vitamin B6, folate
(B9) and vitamin B12) in health and brain function is limited in several respects. As an example, the
major human epidemiological and controlled trial research effort in this area has concentrated almost
exclusively on that small sub-set of B vitamins (folate, vitamin B12 and, to a lesser extent vitamin
B6) that play the most obvious roles in homocysteine metabolism. The multifarious inter-related
roles of the remaining five B vitamins have been largely overlooked. Possibly as a result of this, the
many intervention studies that have involved administering just folic acid ˘ vitamins B12 and/or
B6, have generated equivocal results. Similarly, whilst we have some knowledge of the minimum
levels of each B vitamin required in order to prevent explicit deficiency related diseases, we have
a poor understanding of the negative effects of levels of consumption that lie above the minimum,
but under the optimal level of consumption for these vitamins. Indeed, we have no clear idea of
where the optimal level of consumption may lie. The following review will therefore describe some of
the closely inter-related cellular functions of the entire group of B vitamins in catabolic and anabolic
metabolism; examine evidence from human studies suggesting widespread sub-optimal consumption
of a number of these vitamins in developed societies, and the related case for consumption of these
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vitamins well in excess of governmental minimum recommendations. It will also marshal evidence
from the largely equivocal human literature describing intervention with a small sub-set of B vitamins,
and the more promising literature describing the effects of “multi-vitamin” treatments. Taken together,
these strands of evidence suggest that supplementation with the entire B group of vitamins is a more
rational approach than selecting one, two or three compounds from this sub-group of vitamins.
What Are Vitamins?
Vitamins are a group of organic compounds which are essential for normal physiological
functioning but which are not synthesised endogenously by the body and therefore have to be
sequestered in small quantities from the diet. In total, humans require adequate amounts of 13 vitamins:
four fat soluble vitamins (A, D, E, K) and nine water soluble vitamins, which comprise vitamin C
and the eight B vitamins: thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), vitamin B6,
folate (B9) and vitamin B12. The B vitamins themselves are not grouped on the basis of any chemical
structural similarity, but rather with regards to their water solubility and the inter-related, cellular
coenzyme functions that they play (see Section 2).
In terms of their origins, the B vitamins are typically synthesised by plants, with their synthesis
in plant chloroplasts, mitochondria and the cytosol carefully regulated to the plant’s fluctuating
requirements [1,2]. In the plant they perform the same cellular functions as the roles that they will go
on to play in the animals that consume them, The exception to this is vitamin B12, which is synthesised
by bacteria, and is typically sequestered from animal derived foods, with synthesis having taken place,
for instance, in the foregut of ruminant animals [2].
Although most vitamins are derived ultimately from plants, they are often consumed indirectly
from higher up the food chain in foods of animal origin, including meat, dairy and eggs;
sometimes in forms that have already undergone some form of initial tailoring for bioactivity.
Alternatively, the enzymatic tailoring to achieve their bioactive forms, as described in Table 1, will be
undertaken endogenously.
One key point is that we, and other animals, have generally lost the ability to synthesise
a clade-specific palette of vitamins during our evolution. The apparent evolutionary paradox of
why an organism would benefit from losing the ability to synthesise a compound required for its
survival is resolved by the fact that, during the course of evolution, vitamins have been in ubiquitous
and plentiful supply within the food chain. An organism that can simply sequester its “vitamins”
from the environment may therefore be at an evolutionary advantage, as the process of endogenous
enzymatic de novo synthesis of these compounds would have entailed a disadvantageous cost in
terms of energy expenditure, the need for cellular machinery, and the oxidative stress involved in
metabolism [3,4]. With regards to human vitamin requirements, the clearest example of this process
is the monosaccharide “vitamin C”, which is produced endogenously during normal metabolism
by most other animals. The only exceptions to this are guinea pigs, bats, a few passerine birds and
the anthropoidea (tarsiers, monkeys and apes, including humans). In the case of humans and our
close primate relatives, our inability to synthesise vitamin C is due to a mutation in the gene for
L-gulonolactone, an enzyme in the synthetic pathway of ascorbate, which was lost by our common
ancestor some 35–55 million years ago [5]. Similarly, with respect to the B vitamins, one or more
of the requisite genes expressing the enzymes required for the synthesis of vitamin B6 (pyridoxal
51-phosphate) have been lost on several separate occasions in the branches of the animal kingdom
since the divergence of vertebrates and invertebrates, leaving the majority of animals, including all
mammals, unable to synthesise this compound endogenously [6]. Likewise, the ability to synthesise
folate (vitamin B9) de novo was lost prior to the divergence of the animal kingdom, but with this clade
retaining the synthetic pathway genes required to salvage and recycle folate from dietary sources [7].
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Table 1. The B vitamins: nomenclature, dietary sources, coenzyme forms (roles), symptoms of deficiency, and risk factors (over and above low consumption).
Vitamin Generally Known as
Good Dietary
Sources
RDA 1 (mg) UL 2
Principal Bioactive Coenzymes
(and Principal Coenzyme
Role [8])
Symptoms of Deficiency
Brain Specific Symptoms
of Deficiency
Specific Risk Factors
for Deficiency
B1 Thiamin(e)
Cereals (esp.
whole grain),
brown rice, green
vegetables,
potatoes, pasta,
liver, pork, eggs
1.2/1.1 -
Thiamine pyrophosphate
(Generation of leaving
group potential)
Mild deficiency: general
fatigue/weakness gastro-intestinal
symptoms [9].
Deficiency: “Beri-beri”— Peripheral
nerve damage and cardiovascular
dysfunction leading to: pain, impaired
sensory perception; swelling, weakness
and pain in the limbs; shortness of
breath, irregular heart rate, heart
failure [10]
Mild deficiency: irritability,
emotional disturbances, confusion,
disturbed sleep, memory loss [9].
Deficiency: Wernicke-Korsakoff
syndrome (neurodegeneration,
within the medial thalamus and
cerebellum). Ataxia, abnormal
motor function and eye movement,
amnesia, apathy, confabulation [10]
Alcohol abuse, obesity [9]
B2 Riboflavin
Dairy products,
leafy vegetables,
legumes, liver,
kidneys, yeast,
mushrooms
1.3/1.1 -
Flavoproteins: flavin adenine
dinucleotide (FAD) or flavin
mononucleotide (FMN)
(redox reactions)
Weakness, oral pain/tenderness,
burning/itching of the eyes, dermatitis,
anaemia [11]
Fatigue, personality change, brain
dysfunction [11]
inherited riboflavin
malabsorption/
utilisation (10%–15%
prevalence) [12]
B3 Niacin
Meat, fish, whole
grain cereal,
legumes,
mushrooms, nuts
16/14 35 mg
Nicotinamide adenine
dinucleotide (NAD) and its
phosphate (NADP)
(redox reactions)
Pellagra: dermatitis/photo dermatitis,
alopecia, muscle weakness,
twitching/burning in the extremities,
altered gait, diarrhoea [13]
Depression, anxiety, progressing to
vertigo, memory loss, paranoia,
psychotic symptoms, aggression
(Pellagrous insanity) [13]
Alcohol abuse
B5 Pantothenic acid
Meat, whole grain
cereals, broccoli
5 -
Co-enzyme A (CoA) (acyl
activation and transfer)
Numbness/burning sensations in
extremities, dermatitis, diarrhoea [14]
Encephalopathy, behaviour change,
demyelination [14]
B6
Vitamin B6 (referring
to: pyridoxal,
pyridoxamine,
pyridoxine)
Meat, fish,
legumes, nuts,
bananas, potatoes
1.3/1.3
(1.7/1.5
>50 year)
100 mg
pyridoxal-51-phosphate (PLP)
and pyridoxamine-51-phosphate
(PMP) (Generation of leaving
group potential)
Anaemia
Irritability, impaired alertness,
depression, cognitive decline,
dementia, autonomic dysfunction,
convulsions [15]
Alcohol abuse, age-related
malabsorption, contraceptive
medications [16]
B7 Biotin
Eggs, liver, pork,
leafy vegetables
30 (µg) - biotin (carboxylation reactions)
Seborrheic eczematous rash,
tingling/burning of the extremities [17]
Depression, lethargy,
hallucinations, seizures [17]
Type II diabetes, poor
gluco-regulation [18]
B9 Folic acid/folate
Leafy vegetables,
legumes,
citrus fruits
400 (µg) 1000 µg
tetrahydrofolates inc.
methyltetrahydrofolate
(One carbon transfer) megaloblastic anaemia, peripheral
neuropathy 3, spinal cord lesions,
metabolic abnormalities [19,20]
Affective disorders 4, behaviour
changes, psychosis, cognitive
impairment/decline, dementia (inc
Alzheimer’s disease and vascular
dementia) [19]
Common genetic
polymorphisms (inc. MTHFR
C667T) [21] Low Riboflavin
and B12 [22]
B12
Vitamin B12 (referring
to: the cobalamins)
Meat, fish and
other animal
products
2.4 (µg) -
Methylcobalamin,
adenosylcobalamin
(vicinal rearrangements)
age-related malabsorption [23],
vegetarians, vegans [24]
Genetic polymorphisms [21]
1 Recommended Daily Allowance; 2 Upper limit—Food and Nutrition Board, Institute of Medicine, USA estimated “adequate intake” due to lack of data required to arrive at an RDA;
3 more prevalent for vitamin B12 deficiency; 4 more prevalent for folate deficiency.
Nutrients 2016, 8, 68 4 of 29
Of course, an evolved need to sequester ubiquitous vitamins from food relies on your species
continuing to readily obtain their vitamin requirements from their diet. Our pre-agricultural,
micro-nutrient rich diet, which comprised of plant-derived vegetables, fruits and nuts, with fish and
meat when available, has been superseded by our typical contemporary, high-energy, highly digestible,
micronutrient-depleted diet. It has been suggested that this divergence between our evolutionary diet
and our modern diet underlies the high levels of vitamin deficiencies seen in developed societies and
many of the associated “lifestyle diseases” such as obesity, cardiovascular disease and dementia [25–28].
Certainly, research suggests that increased adherence to the “Mediterranean diet” (typified by high
consumption of fruit, vegetables, legumes, complex rather than simple carbohydrates, olive oil, and
red wine, and moderate consumption of fish and white meat), is associated with increased levels of all
vitamins and minerals, including B vitamins. Conversely, increased adherence to the “Western” dietary
pattern (typified by high consumption of processed meat, red meat, butter, high-fat dairy products,
eggs, and refined grains and sugars) is associated with a general pattern of decreasing vitamin and
mineral intake. This includes most of the B vitamins, with the notable exception of vitamin B12, which
is particularly abundant in red meat [29,30].
2. Mechanisms of Action and Functions of B Vitamins
B vitamins act as coenzymes in a substantial proportion of the enzymatic processes that underpin
every aspect of cellular physiological functioning. As a coenzyme the biologically active form of the
vitamin binds within a protein “apoenzyme” creating a “holoenzyme”, thereby increasing the resultant
enzyme’s competence in terms of the diversity of reactions that it can catalyse [8]. In this role, the
B vitamins play key interacting roles in the majority of cellular functions. As an example of their
ubiquity, the primary bioactive form of vitamin B6, pyridoxal 5
1-phosphate, is an essential cofactor
in the functioning of over 140 separate ubiquitous enzymes required for the synthesis, degradation,
and interconversion of amino acids [15], whereas the active coenzyme form of pantothenic acid,
coenzyme A (CoA), is an obligatory co-factor for approximately 4% of all mammalian enzymes [31].
Less often B vitamins also function as direct precursors for metabolic substrates; for example, CoA is
also acetylated to form acetyl-CoA, an intermediate compound in both the generation of cellular energy
and the synthesis of multiple bioactive compounds. Similarly, niacin is a precursor for ADP-ribose,
which functions in multiple non-enzymatic cellular roles.
Overall, the plethora of functions undertaken by B vitamins can generally be subdivided into their
roles in catabolic metabolism, leading to the generation of energy, and anabolic metabolism, resulting
in the construction and transformation of bioactive molecules.
Catabolic energy production: One or more of the B vitamins are involved in every aspect of the
absolutely essential catabolic process of generating energy within cells [17], and deficiency in any one
B vitamin will have negative consequences for this process. Of particular relevance here, the active
forms of thiamine, riboflavin, niacin, and pantothenic acid are essential co-enzymes in mitochondrial
aerobic respiration and cellular energy production via their direct roles in the citric acid cycle, the
electron transport chain and the resultant formation of adenosine triphosphate (ATP), the cell’s
energy currency. Acetyl-CoA (incorporating pantothenic acid) provides the main substrate for this
cycle [9,11,14,32–34]. In addition, thiamine and biotin/vitamin B12 play unique, intersecting, essential
roles in the mitochondrial metabolism of glucose [9] and fatty acids and amino acids, respectively [11],
thereby contributing substrates to the citric acid cycle. The inter-related contribution of the B vitamins
to the citric acid cycle and electron transport chain, the central catabolic process in mitochondria,
is illustrated in Figure 1.
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Figure 1. The role of B-vitamins in mitochondrial energy production. The citric acid cycle
(tricarboxylic/Krebs cycle) is a series of chemical reactions that generate energy, in the form of ATP, in
the mitochondria of eukaryotes. Carbohydrates, fats and proteins are first converted to acetyl-CoA,
most often via pyruvate, and then undergo eight enzymatic reactions that result in the production of
NADH and FADH2, which transfer the energy generated by the citric acid cycle to the electron transport
chain. This in turn leads to the synthesis of ATP, the energy currency of cells. B vitamins contribute
(as shown) to this process as co-factors/enzymes such as FAD (B2), NAD (B3) and as a component of
CoA (B5), or Co-enzyme Q10 (B5). The intermediate compounds of the cycle are also sequestered as
substrates for the synthesis of other compounds, including amino acids and fatty acids, and several
subsequently have to be replenished by anaplerotic synthesis, taking place outside of the cycle. The
most prevalent examples are the augmentation of succinyl-CoA from α-ketobutyrate generated from
methionine within the methionine cycle (see Figure 2), and synthesis of oxaloacetate direct from
pyruvate. Abbreviations: BCKDC, branched-chain α-ketoacid dehydrogenase complex; CS, citrate
synthase; CoA, coenzyme A; FAD/FADH2, flavin adenine dinucleotide (oxidised/reduced); IDH,
isocitrate dehydrogenase; NAD, nicotinamide adenine dinucleotide (+/H = oxidised/reduced); MDH,
malate dehydrogenase; MCM, methylmalonyl-CoA mutase; OGDH, α-ketoglutarate dehydrogenase;
PCC, propionyl-CoA Carboxylase; PC, pyruvate carboxylase; PD, pyruvate dehydrogenase; SCS,
succinyl-CoA synthetase; SQR, succinate-coenzyme Q reductase.
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Figure 2. The interlinked folate and methionine cycles. Dietary folate enters the folate cycle and
rotates through several enzymatic modifications which generate the one-carbon units required for the
synthesis of DNA/RNA and the methyl groups required to regenerate methionine from homocysteine.
The “methionine cycle” provides the methyl groups required for all genomic and non-genomic
methylation reactions in the form of S-adenosyl methionine (SAM). These two enzymatic cycles
are essential to cellular function, including via interactions with other pathways. As an example
of the latter, the re-salvaging from dihydrobiopterin of tetrahydrobiopterin, an essential cofactor
in trace amine and catecholamine neurotransmitter synthesis and nitric oxide production, is rate
limited by provision of the enzyme dihydrofolate reductase produced by the folate cycle. * FAD
(vitamin B2) is a cofactor for methionine synthase reductase in the recycling of the vitamin B12
cofactor for methionine synthase. Abbreviations: AADC, aromatic L-amino acid decarboxylase;
AAAH, aromatic amino acid hydroxylases; ATP, adenosine triphosphate; BH2, dihydrobiopterin;
BH4, tetrahydrobiopterin; CBS, cystathionine beta synthase; CGL, cystathionine gamma-lyase; DHFR,
dihydrofolate reductase; dTMP, thymidine monophosphate; dUMP, deoxyuridine monophosphate;
GR, glutathione reductase; GSSG, glutathione disulphide; MAT, methionine adenosyltransferase; MS,
methionine synthase; MTHFR, methyltetrahydrofolate reductase; NOS, nitric oxide synthase; SAH,
S-adenosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase; SAM, S-adenosyl methionine;
SH, serine hydroxymethyltransferase; THF, tetrahydrofolate; TS, thymidylate synthase.
Anabolic processes: The vitamin-dependent, citric acid cycle furnishes not only energy, but also
the intermediaries for the biosynthesis of numerous key compounds, including amino acids, fatty
acids and pyrimidines. A number of B vitamins also play essential roles in all aspects of one-carbon
metabolism [32–35], the process by which functional compounds, such as amino acids, purines,
and pyrimidines, as well as methyl groups required by molecules in order for them to take part in
biochemical reactions, are created within cells by the addition of single units of carbon. Of particular
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relevance, several B vitamin coenzymes are intrinsic contributors to two ubiquitous inter-related
cellular processes: the “folate cycle”, during which tetrahydrofolate (one active form of folate) from
the diet cycles through several enzymatic modifications which ultimately provide the one-carbon
units required for one carbon metabolism, and the “methionine cycle” during which the amino
acids methionine and homocysteine are interconverted, resulting in the synthesis of the methyl
groups required for all genomic and non-genomic methylation reactions in the form of S-adenosyl
methionine (SAM). These two enzymatic cycles are essential to cellular function, including via
interactions with other pathways. As an example of the latter, the re-salvaging from dihydrobiopterin
of tetrahydrobiopterin, an essential cofactor in trace amine and catecholamine neurotransmitter
synthesis and nitric oxide production, is rate limited by provision of the enzyme dihydrofolate
reductase produced by the folate cycle [36,37]. Similarly, the trans-sulfuration pathway that converts
homocysteine to cysteine, ultimately leading to the synthesis of the potent endogenous antioxidant
glutathione and the generation of substrates for the citric acid cycle, is a direct product of themethionine
cycle. Whilst the roles of folate and vitamins B6 and B12 are well recognised in these intersecting
cycles (see “The homocysteine hypothesis” below), the contribution of other B vitamins is rarely
acknowledged. In this regard, the active form of riboflavin is a coenzyme with methyltetrahydrofolate
reductase (MTHFR) in the folate cycle, and rate limits the recycling of methionine synthase in
the methionine cycle [22]. Similarly, niacin, in the form of NAD, is a necessary co-factor for the
enzymes dihydrofolate reductase in the folate/tetrahydrobiopterin cycles and S-adenosylhomocysteine
hydrolase in the methionine cycle. The eventual functional products of these intersecting cellular cycles
and the rate-limiting contributions made by the full range of B vitamins are illustrated in Figure 2.
Just one of the many consequences of a deficiency in any of these B vitamins (see Figure 2)
is a potential hampering of the natural breakdown and recycling of homocysteine, leading to
its accumulation and a number of potential, negative cellular consequences. Alongside this, the
observation that homocysteine levels are increased in those suffering a range of pathologies including
cardiovascular and neurodegenerative diseases has resulted in the “homocysteine hypothesis” that has
driven much of the human research into the effects of B vitamins on brain function. This hypothesis
will be described and discussed in more detail below.
2.1. Brain Specific Roles of B Vitamins
The brain is by far the most metabolically active organ in the body, representing only 2% of body
weight but accounting for over 20% of the body’s total energy expenditure [38]. The B vitamins’ general
metabolic functions, alongside their roles in neurochemical synthesis, may therefore be conceived
as having a particular impact on brain function. Indeed, the importance of the B vitamins for brain
function is illustrated by the fact that each vitamin is actively transported across the blood brain barrier
and/or choroid plexus by dedicated transport mechanisms. Once in the brain, specific cellular uptake
mechanisms dictate distribution, and, whilst the B vitamins all have high turnovers, ranging from
8% to 100% per day, their levels are tightly regulated by multiple homeostatic mechanisms in the
brain [39,40]. This guarantees that brain concentrations remain comparatively high. For example,
the oncentration of methyltetrahydrofolate (the principal circulating form of folate) in the brain is four
times that seen in plasma [39], whereas biotin and pantothenic acid exist in the brain at concentrations
of up to 50 times that seen in plasma [41].
2.1.1. Thiamine (Vitamin B1)
Thiamine is a coenzyme in the pentose phosphate pathway, which is a necessary step in the
synthesis of fatty acids, steroids, nucleic acids and the aromatic amino acid precursors to a range of
neurotransmitters and other bioactive compounds essential for brain function [9]. Thiamine plays
a neuro-modulatory role in the acetylcholine neurotransmitter system, distinct from its actions as
a cofactor during metabolic processes [42] and contributes to the structure and function of cellular
membranes, including neurons and neuroglia [35].
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2.1.2. Riboflavin (Vitamin B2)
The two flavoprotein coenzymes derived from riboflavin, FMN and FAD are crucial rate limiting
factors in most cellular enzymatic processes. As an example, they are crucial for the synthesis,
conversion and recycling of niacin, folate and vitamin B6, and for the synthesis of all heme proteins,
including hemeglobin, nitric oxide synthases, P450 enzymes, and proteins involved in electron transfer
and oxygen transport and storage [11]. The flavoproteins are also co-factors in the metabolism of
essential fatty acids in brain lipids [12], the absorption and utilisation of iron [43], and the regulation
of thyroid hormones [11]. Dysregulation of any of these processes by riboflavin deficiency would be
associated with its own broad negative consequences for brain function. Riboflavin derivatives also
have direct antioxidant properties and increase endogenous antioxidant status as essential cofactors in
the glutathione redox cycle [44].
2.1.3. Niacin (Vitamin B3)
A vast array of processes and enzymes involved in every aspect of peripheral and brain cell
function are dependent on niacin derived nucleotides such as nicotinamide adenine dinucleotide
(NAD) and NAD phosphate (NADP). Beyond energy production, these include oxidative reactions,
antioxidant protection, DNA metabolism and repair, cellular signalling events (via intracellular
calcium), and the conversion of folate to its tetrahydrofolate derivative [45]. Niacin also binds
agonistically at two G protein receptors, the high affinity Niacin receptor 1 (NIACR1), responsible for
the skin flush associated with high intake of niacin, and the low affinity NIACR2. Niacin receptors are
distributed both peripherally in immune cells and adipose tissue, and throughout the brain. Currently
established roles include modulation of inflammatory cascades [46,47] and anti-atherogenic lipolysis
in adipose tissue [48,49]. NIACR1 receptor populations have been shown to be down-regulated in the
anterior cingulate cortex of schizophrenia sufferers [46] and upregulated in the substantia nigra of
Parkinson’s disease sufferers, (a group that have low niacin levels generally) with levels correlating
with poorer sleep architecture in this group [50]. A recent case study demonstrated that 250 mg niacin
administration modulated peripheral immune cell NIACR1 expression and attenuated the disturbed
sleep architecture associated with Parkinson’s disease [51].
2.1.4. Pantothenic Acid (Vitamin B5)
This vitamin is a substrate for the synthesis of the ubiquitous coenzyme A (CoA). Beyond its
role in oxidative metabolism, CoA contributes to the structure and function of brain cells via its
involvement in the synthesis of cholesterol, amino acids, phospholipids, and fatty acids. Of particular
relevance, pantothenic acid, via CoA, is also involved in the synthesis of multiple neurotransmitters
and steroid hormones [14].
2.1.5. Vitamin B6 (Pyridoxine, Pyridoxal, Pyridoxamine)
Beyond its role as a necessary cofactor in the folate cycle (see above and folate section below),
the role of vitamin B6 in amino acid metabolism makes it a rate limiting cofactor in the synthesis
of neurotransmitters such as dopamine, serotonin, γ-aminobutyric acid (GABA), noradrenaline
and the hormone melatonin. The synthesis of these neurotransmitters is differentially sensitive to
vitamin B6 levels, with even mild deficiency resulting in preferential down-regulation of GABA
and serotonin synthesis, leading to the removal of inhibition of neural activity by GABA and
disordered sleep, behaviour, and cardiovascular function and a loss of hypothalamus-pituitary
control of hormone excretion. Vitamin B6 also has a direct effect on immune function and gene
transcription/expression [15] and plays a role in brain glucose regulation [52]. More broadly,
levels of pyridoxal-51-phosphate are associated with increased functional indices and biomarkers
of inflammation, and levels of pyridoxal-51-phosphate are down-regulated as a function of more
severe inflammation [53,54], potentially as a consequence of pyridoxal-51-phosphate’s role either in
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the metabolism of tryptophan or in one-carbon metabolism [53]. This role is particularly pertinent as
inflammatory processes contribute to the aetiology of numerous pathological states including dementia
and cognitive decline [55].
2.1.6. Biotin (Vitamin B7)
The brain is particularly sensitive to the delivery and metabolism of glucose. Biotin plays
a key role in glucose metabolism and haemostasis, including regulation of hepatic glucose uptake,
gluconeogenesis (and lipogenesis), insulin receptor transcription and pancreatic β-cell function [18].
Frank deficiency in biotin is rarely reported, although lower circulating levels of biotin have been
reported in those suffering gluco-regulatory dysfunction, for instance Type II diabetes, alongside an
inverse relationship between fasting plasma glucose and biotin levels [18].
2.1.7. Folate (Vitamin B9) and Vitamin B12 (Cobolamin)
The functions of these two vitamins are inextricably linked due to their complementary roles
in the “folate” and “methionine” cycles. Indeed, a deficiency in vitamin B12 results in a functional
folate deficiency, as folate becomes trapped in the form of methyltetrahydrofolate [11,19]. An actual or
functional folate deficiency, with an attendant reduction in purine/pyrimidine synthesis and genomic
and non-genomic methylation reactions in brain tissue, leads to decreased DNA stability and repair
and gene expression/transcription, which could hamper neuronal differentiation and repair, promote
hippocampal atrophy, demyelination and compromise the integrity of membrane phospholipids
impairing the propagation of action potentials [45]. Folate related downregulation of the synthesis of
proteins and the nucleotides required for DNA/RNA synthesis, has ramifications for rapidly dividing
tissue in particular, and therefore underlies the foetal developmental disorders and megaloblastic
anaemia (alongside aspects of neuronal dysfunction), associated with either folate or vitamin B12
deficiency [11,19,45]. The efficient functioning of the folate cycle is also necessary for the synthesis and
regeneration of tetrahydrobiopterin, an essential cofactor for the enzymes that convert amino acids
to both monoamine neurotransmitters (serotonin, melatonin, dopamine, noradrenaline, adrenaline),
and nitric oxide [56,57] (see Figure 2).
The importance of all of the B vitamins to brain function is illustrated by the neurological
and psychiatric symptoms commonly associated with deficiency in any one of these eight
vitamins [11,45,58,59] (see Table 1). For example, the primary symptoms of vitamin B6 deficiency
are neurological, including depression, cognitive decline, dementia, and autonomic dysfunction [15]
and vitamin B12 deficiency is often manifested in the form of neurological symptoms prior to the
appearance of more typical haematological changes [20]. Notably, whilst about a third of those
suffering folate or vitamin B12 deficiency present only with anaemia, a similar proportion present
only with neuropsychiatric symptoms. Indeed, more than a third of psychiatric admissions have been
found to be suffering deficiencies in folate or vitamin B12 [19].
3. The Homocysteine Hypothesis
No description of the mechanisms of action of the B vitamins would be complete without some
consideration of the predominant mechanistic theory that has driven much of the human research in
this area. The “homocysteine hypothesis” originally stemmed from the observation that increased
fasting plasma levels of the potentially toxic amino acid homocysteine were an independent predictor
of cardiovascular disease [60,61],with this observation subsequently extended to cognitive function [62],
Alzheimer’s disease and dementia [63]. In essence, the hypothesis attributedmild tomoderate increases
in homocysteine levels with being a causal contributor to these disease states. Insufficiencies in several
of the key vitamins involved in effectively recycling homocysteine in the methionine cycle, in particular
folate, but also vitamins B12 and B6, were then implicated as the underlying cause [61]. Themechanisms
by which homocysteine has been hypothesised to have these detrimental effects on brain function
include its theoretical roles in increasing oxidative stress, the inhibition of methylation reactions,
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increased damage to DNA and dysregulation of its repair, and direct and indirect neurotoxicity leading
to cell death and apoptosis. These processes are suggested to then lead to general effects such as the
accumulation of beta-amyloid, hyper-phosphorylation of tau, brain tissue atrophy and compromised
cerebrovascular circulation [64].
This hypothesis has been the driver not only for the majority of observational studies investigating
epidemiological relationships between vitamins and cardiovascular or brain function, but also for
a huge research effort that has seen a flood of clinical trials that have involved the administration of folic
acid, either alone or in combination with vitamin B12, and less frequently, vitamin B6. These studies
have been conducted on the basis that increasing the levels of these vitamins will reliably reduce
homocysteine levels. However, the results of the intervention trials have been entirely equivocal.
As an example, meta-analyses of the data from 17 trials, involving 39,107 participants [65] and
12 trials involving 47,429 participants [66] found that whereas administering folic acid ˘ vitamins
B12/B6 reliably reduced homocysteine levels, these vitamins had no protective effect against
cardiovascular or cerebrovascular disease events or all-cause mortality. The findings with regards
to brain function, reviewed below, are equally equivocal. In addition, studies investigating the
relationship between a common genetic polymorphism associated with higher homocysteine levels
(methylenetetrahydrofolate reductase (MTHFR) 677TT) and cardiovascular disease [61] and cognitive
function [67] have also been equivocal. These findings suggest that homocysteine is likely to be
a simple biomarker or epiphenomenon related either to the circulating levels of the relevant vitamins
or a disease related mechanism or process [61,68–70].
One unfortunate consequence of the “homocysteine hypothesis” is that it has effectively funneled
the majority of clinical trial research in this area towards elucidating the effects of folic acid, and to
a decreasing extent vitamin B12 followed by vitamin B6. The potential effects and roles of the other five
B vitamins have been almost entirely ignored, despite the fact that the entire palette of B vitamins work
intricately in concert. As an example, staying with the homocysteine theme, the status of folate and
vitamin B6/B12 are themselves dependent on levels of riboflavin derived flavoproteins. Riboflavin is
also essential for the metabolism of homocysteine as a cofactor for methylenetetrahydrofolate reductase
(MTHFR) and methionine synthase reductase (MTRR) [11,12,22]. In line with this, homocysteine levels
have been shown to correlate negatively with plasma riboflavin and dietary riboflavin intake [71,72],
and supplementation with riboflavin has been shown to attenuate both increased homocysteine
levels and blood pressure in individuals with the MTHFR 677TT polymorphism [73,74]. Although
it has received even less attention than riboflavin, it is notable that niacin is also a necessary
cofactor for the enzymes dihydrofolate reductase and S-adenosylhomocysteine synthase in the
folate/tetrahydrobiopterin andmethionine cycles, respectively, and that all of the remaining B vitamins
play roles in the interlinked folate/methionine and citric acid cycles [8,11,14] (see Figures 1 and 2).
The potential limitations of administering a restricted range of B vitamins are illustrated by
evidence showing that approximately a third of supplementation studies to date have involved the
administration of folic acid alone [65,66]. As noted above, folate and vitamin B12 are intimately
interlinked within the folate/methionine cycles, and increasing the level of folate can mask the accrual
of permanent neurological damage associated with a specific vitamin B12 deficiency [20]. A striking
illustration of this was provided by an epidemiological study by Morris et al. [75] who reported that
high folate status was associated with protected cognitive function, but only in those with normal
vitamin B12 status, with this relationship reversed in participants with low vitamin B12 status. For this
group, high folate status exacerbated the detrimental effect of vitamin B12 deficiency, increasing the risk
of cognitive impairment and anaemia by a factor of five, compared to those with normal vitamin status.
A further study also demonstrated that low vitamin B12 status was associated with a significantly
increased decline in cognitive performance over the subsequent eight years, with this effect exacerbated
in those having high levels of folate, or those taking folic acid supplements [76]. Alongside these
observations it is interesting to note that in one study supplementation with folic acid also significantly
increased the proportion of participants with riboflavin deficiency [72].
Nutrients 2016, 8, 68 11 of 29
It is also notable, firstly, that supplementation with folic acid may not be effective in terms of
regulating homocysteine: a recent study showed that folic acid supplementation reduced plasma
homocysteine levels as expected, but left the more important cellular levels of homocysteine untouched,
with evidence suggesting that cellular one-carbon metabolism was also disturbed [77]. Secondly, folate
may affect physiological functioning via an alternative mechanism, for instance via the role the folate
cycle plays in the synthesis and regeneration of tetrahydrobiopterin [57], a folate-dependent rate
limiting cofactor in the enzymatic pathways to both nitric oxide and monoamine neurotransmitter
synthesis [37,78,79]. This mechanism would accommodate the observation that folate increases
endothelial vasodilation via a mechanism entirely unrelated to homocysteine [57,79] and would
accommodate epidemiological observations of a relationship between reduced folate status and
depression and disturbed cognitive function [56,78,80].
It seems reasonable to conclude, from the above and the following, that concentrating solely on
one potential hypothesis as to the mechanisms of action of a small group of vitamins with multifarious
complex cellular functions, at the expense of elucidating the mechanisms and effects of a broader
group of inter-related vitamins, in hindsight, may not be a rational approach to research in this area.
4. B Vitamin Deficiencies in Developed Societies
A general assumption tends to bemade that the populations of developed countries have adequate
nutrition, and are therefore free from deficiencies in essential micronutrients. In order to encourage
adequate nutrition, governments typically define a set of “dietary reference intakes” or similar for
individual nutrients. These always include something akin to the “recommended dietary allowance”,
or RDA. These government figures describe the minimum daily intake of the specific nutrient that is
considered to be sufficient to meet the nutritional requirement of the majority of the healthy population.
However, “meeting the requirements” in this context typically refers to simply preventing chronic,
nutrition related diseases or a disease state related to a specific deficiency of that nutrient (see Table 1).
RDAs are population statistics and they therefore represent rough estimates of the average
requirement of individuals within a group/population, with an adjustment for the variations in
the need for the nutrient among the individuals that make up the population. However, for most
micronutrients some of the information that would be required to accurately calculate the daily
requirement is either unknown or incomplete, and the recommendations are therefore made on the
basis of a number of assumptions and considerations that could lead to large variations in the eventual
RDA [81,82]. These figures have also changed little in the last four decades, despite emerging evidence
of striking individual differences in the absorption and excretion of vitamins as a consequence of a wide
range of factors, including specific genetic polymorphisms, gender, ethnicity, endocrine dysfunction,
thyroid function, the habitual co-consumption of medicines, drugs, alcohol and other dietary factors,
obesity, overall energy consumption, vigorous exercise, and age [9,21,45,83–86]. These gaps in our
knowledge question the very existence of a “normal” population [87], and suggest that RDAs are,
to some extent, arbitrary figures.
Government figures also show that sizeable minorities of the populations of developed countries
fail to consume even the minimum recommended quantity of any given micronutrient. As an example,
Troesch et al. [88] presented data showing that a sizeable proportion of the populations of the US
and several European countries consume less than the RDA for each of the five B vitamins that they
assessed. They note that “a gap exists between vitamin intakes and requirements for a significant
proportion of the population”. As a result, studies assessing the blood levels of vitamins show that
small but significant proportions of the populations of developed countries have biochemical levels
of each of the B vitamins that may well predispose them to deficiency related diseases. For example,
UK government figures [89] show adult deficiency levels of 3% for vitamin B12 and 5% for folate,
with these figures increasing to 5% and 12%, respectively, in the lower socio-economic portion of
the population [90]. In the US, the story is similar. For instance, recent US government data [91]
demonstrated that 10.5% of the entire US population were biochemically deficient in vitamin B6.
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A subsequent independent analysis that excluded the substantial minority taking supplements
containing vitamin B6 demonstrated much higher deficiency rates of between 23% and 27% for
adults, depending on age [16]. Similarly, larger proportions of “at risk” groups exhibit deficiencies in
vitamin B12. As an example, more than 30% of a nationally representative US sample of adults over
60 years of age were below deficiency levels (<148 pmol/L) [75]. This may well be due to an age-related
impairment in the absorption of the protein-bound vitamin B12 found in food [23], although it should
be noted that deficiency levels in this vitamin are similar for vegetarians and vegans, simply due to
a lack of consumption [24,92]. It has also been suggested that the available evidence suggests that
the typical cut-off point defining deficiency in B12 is simply set too low, with negative health effects
associated with reduced vitamin B12 extending well into “normal” levels of this vitamin [93]. Thiamine
deficiency levels are also higher in the elderly, with 16%–18% deficient [94]. It is also worth noting
that, whilst riboflavin deficiency levels are under-researched, biochemical deficiency is potentially
widespread due to the high prevalence of an inherited restriction of riboflavin absorption/utilisation
that affects 10%–15% of the world population [12].
One factor that also continues to exert an upwards pressure on deficiency levels is the paradoxical
malnutrition associated with obesity. This is becoming ever more prevalent as levels of obesity continue
to rise across developed nations. For instance, some 35% of the adult US population was classified as
obese in 2011/12 [95]. This deficiency phenomenon is predicated largely on the basis that obesogenic
diets are typically biased towards energy rich processed foods that are high in fats and simple sugars
but low in micronutrients, leading to deficiencies in a range of vitamins and minerals [96]. This may be
particularly prevalent for vitamins involved in, and depleted by, metabolism. For instance, thiamine
plays an essential role in glucose metabolism, and between 15.5% and 29% of obese patients examined
prior to bariatric surgery across a number of studies were found to be deficient. Similarly, thiamine
deficiency rates have been reported to vary between 17% and 79% in patients suffering from the
gluco-regulatory disease diabetes [9,18]. In a similar vein, both Type II diabetes and increased fasting
plasma glucose levels have been found to be associated with lower levels of biotin [18].
Of course, an individual may not be technically deficient in a micronutrient, but may still be in the
much more common state of “marginal deficiency” which will still predispose them to an increased
risk of a number of more general disease states (e.g., [93,97,98]). The US government, in a recent report
on micronutrient levels in the US population [91], gave their first official acknowledgement of the
dangers of non-deficient but less than optimal nutritional status when the report stated that, whereas
the effects of outright dietary deficiencies are well documented, “In addition, recent findings have
determined that less than optimal biochemical concentrations (representing suboptimal status) have
been associated with risks of adverse health effects”. Levels of marginal deficiency are, by definition,
much higher than levels of outright deficiency for all of the vitamins. As an example, both Smith and
Refsum [93] and Tucker et al. [23] noted that the neurological/psychological manifestations of vitamin
B12 insufficiency can be evident at much higher serum levels of this vitamin than those marking
deficiency. Indeed, Tucker et al. [23] found that whilst 9% of their sample of 3000 adults were frankly
deficient in vitamin B12 (<148 pmol/L), over 38% had serum levels (<258 pmol/L) suggesting marginal
deficiency. These figures are broadly in line with analyses of US data showing that 17.8% of all adults
in the USA were marginally deficient in vitamin B12 using a more stringent cut-off (220 pmol/L) [96],
and analyses of more recent population data showing that over 20% of the over 50 years age group
in the US were marginally deficient in vitamin B12 between 2001 and 2006 [99]. In terms of other
B vitamins, a striking 66% of the UK non-elderly adult population were at least marginally deficient in
riboflavin (as assessed by the erythrocyte glutathione reductase activation test (EGRAC)) [89], with
a similar figure of 54% derived in another study when a slightly more stringent EGRAC was used [72].
Taken as a whole, these figures suggest that a very sizeable proportion of the populations
of developed countries are suffering deficiency or marginal deficiency in one or more B vitamins
that may, at the least, dispose them to a variety of chronic diseases. Just as the minimum daily
requirement of many micronutrients is simply unknown at present, the optimal level has received
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no attention at all. As one review paper [100] notes, even the governmental agencies responsible
for defining dietary recommendations acknowledge that the benefits of micronutrient consumption
may continue on a continuum well above the RDA. Clearly, common sense dictates that the optimal
level of consumption of any nutrient will not merely be the level that prevents diseases related to
a deficiency, or even marginal deficiency, in that nutrient. In line with this, a wealth of epidemiological
evidence suggesting relationships between the increased consumption/biochemical levels of a number
of vitamins, and benefits for cardiovascular function, cognitive function and decreased incidence
of dementia clearly show that individuals derive additional relevant physiological benefits from
consumption of micronutrients well in excess of the RDA, and biochemical levels above those denoting
marginal deficiency (see [98,101]). This evidence will be summarised below.
5. HowMuch Is Enough?
As the B vitamins are water-soluble, any excess is generally excreted in urine. On the one
hand, this means they are typically safe at doses much higher than the RDA, but on the other hand,
they require a more consistent consumption than the fat soluble vitamins. In terms of safety, only
three of the eight B-vitamins have been ascribed any upper limit for daily consumption, with the
remainder considered safe at any dose [14,20]. In the case of folic acid, which is ascribed RDAs
typically between 200 and 400 µg/day, the upper limit is generally set at 1000 µg/day simply on
the basis that increased folate can mask the symptoms of vitamin B12 deficiency, allowing a hidden
accumulation of permanent damage related to the latter vitamin [102]. It should also be noted that
evidence suggests a potential detrimental effect of consuming high doses of folic acid, and therefore
raised levels of un-metabolised folic acid, on normal folate metabolism and immune function. High
folate levels may also interfere with the anti-folate medications prescribed for a number of conditions
(e.g., rheumatoid arthritis, psoriasis, cancer, bacterial infections, malaria) and exert biphasic effects with
regards to cancer; conferring protection at lower concentrations but increasing carcinogenesis at higher
concentrations. However, to date there is no consensus as to the blood levels of folates that might cause
harm [103]. The upper limit for niacin is set at 35 mg (US/Canada), with this predicated simply on its
ability to cause temporary flushing of the skin at doses in excess of 100 mg, although nausea, vomiting,
diarrhoea and in very rare cases liver damage have been noted following extended consumption of
doses of a gram and more [8]. The final B vitamin with an ascribed upper limit is vitamin B6 which
has an upper limit set at 100 mg/day (approximately 75 ˆ RDA) in the US on the basis of case reports
of reversible sensory neuropathy following doses in excess of 1000 mg taken for extended periods.
However, it is notable that multiple clinical trials entailing consuming up to 750 mg/day of vitamin B6
for a number of years have demonstrated a lack of neuropathic side effects [15].
As noted above, the optimum level of any micronutrient must lie well above the RDA, and the
B vitamins can generally be consumed at many times the RDA. This raises the question of howmuch of
these vitamins should we consume? Whilst this issue is poorly understood to date, several strands of
evidence suggest that increasing consumption well above the RDA should be a more effective strategy.
The first strand of evidence for this comes from dose-ranging studies that have demonstrated increases
in bioavailability persisting well above the RDA. For instance, Smithline et al. [104] demonstrated
a shallow, linear dose response following single oral doses of thiamine in terms of whole blood
and plasma levels up to the maximum administered dose of 1500 mg (corresponding to more than
1000 times the RDA), in healthy subjects. Similarly, one study [105] demonstrated an approximately
linear dose-response in serum levels of vitamin B12 among adults which persisted to more than
100 µg/day of supplement use (40 ˆ RDA), but with a plateau in levels at lower doses being evident
for middle-aged and older adults. A subsequent meta-analysis [106] of the results of vitamin B12
supplementation studies with doses ranging from approximately 1 RDA up to 400 RDA (i.e., 1000 µg)
administered for between four weeks and two years, showed that for every doubling of intake above
the RDA, blood levels of Vitamin B12 continued to increase by 11%, while methylmalonic acid levels,
an indicator of deficiency, decreased by 7%. This dose response is potentially most relevant to older
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adults (>50 years), who typically suffer age associated malabsorption of dietary vitamin B12 and
therefore high levels of insufficiency. Certainly, in a dose-response study, Eussen [107] found that
the most effective dose for normalising vitamin B12 status in marginally deficient older adults was
500 µg/day (200 ˆ RDA). It is also notable that a dose of 1 mg/day folic acid (2.5 ˆ RDA) for 12 months
was required to achieve maximal steady state erythrocyte folate concentrations in older adults [108].
In terms of potentially beneficial physiological responses to increased dosage, Eussen et al.’s [107]
study was particularly interesting in that it also demonstrated a linear negative dose-response up to the
maximum dose of 1000 µg/day Vitamin B12 (i.e., 400 ˆ RDA) with regards to the reductions in plasma
levels of homocysteine. A clear dose response was also evident in a meta-analysis of 25 folic acid
studies, with 800 µg/day (2–4 ˆ RDA) required to achieve peak reductions in plasma homocysteine
of 23%, with the addition of a median dose of 400 µg/day vitamin B12 (i.e., 166 ˆ RDA) associated
with a further fall of 7% [109]. Interestingly, single doses of folic acid, and chronic supplementation
with vitamin B6, folic acid and their combination, all taken at a minimum of 12 times their RDAs
have all been shown to improve endothelial function in patient groups or following laboratory
induced endothelial dysfunction. These effects were independent of any effect of these vitamins
on homocysteine levels [110,111]. In population studies, intakes of vitamin B6 well in excess of the
RDA, along with associated biochemical levels of pyridoxal-51-phosphate, have also been found to
be inversely related to a range of inflammatory biomarkers, with those individuals exhibiting higher
levels of inflammatory biomarkers requiring several times the RDA of vitamin B6 merely to avoid
deficiency [53,54].
With regards to riboflavin, the highest of two doses (4 mg/day, i.e., 3 ˆ RDA) administered
for eight weeks to young females had the greatest effects both on riboflavin status and benefits to
haematological parameters [43]. It is also notable that, whilst riboflavin has no demonstrable toxicity,
the maximum daily intestinal absorption is approximately 20 times the RDA of 1.3 mg. Doses of this
magnitude for up to eight weeks are also required to replenish riboflavin levels and correct enzymatic
activity in the 10%–15% of the population who have an inherited restriction in their ability to absorb
riboflavin [12].
Evidence (see below) also shows that “mega-doses” of biotin and niacin at between 30 and
500 times the RDA exert beneficial physiological effects, in terms of glycaemic control, insulin
sensitivity, and anti-inflammatory properties. As an example, niacin, at pharmacological doses
in excess of 1 g/day, has been shown to exert anti-inflammatory properties via niacin receptor
interactions [47,112] and improve insulin sensitivity, reduced adipocyte size, and exert anti-atherogenic
effects on lipid profiles, whilst increasing the expression of niacin receptors in adipocytes [49].
In general, epidemiological evidence suggests that the benefits of B vitamins extend well beyond
the accepted biochemical cut-offs for deficiency or marginal deficiency [101] and that consuming
the RDA for some B vitamins would still leave large proportions of the population at risk of
insufficiency [16]. Indeed, there would seem to be little evidence for supplementing with the bare
minimum requirement (RDA) given the dose-response to B vitamins in terms of bioavailability and
physiological benefits.
6. Do B Vitamins Have an Impact on Brain Function?
Given that B vitamins are essential for every aspect of brain function, and that large proportions
of the population of developed societies have less than optimal levels of vitamins, it would be expected
that a relationship would be evident between vitamin consumption and mental function both in terms
of epidemiological studies and controlled intervention trials. The driver for much of the research
conducted to date in both of these domains has been the “homocysteine hypothesis” described above.
Concentrating on this one unproven hypothesis has resulted in both observational and controlled trial
research being focussed disproportionately on just three of the vitamins—folate and vitamins B6 and
B12. However, the observational and the controlled trial research concentrating on these three vitamins
could be seen as generating somewhat different conclusions.
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6.1. Observational Studies
To give an idea of the size of the epidemiological research effort in this area, a review paper
published in 2008 by Smith [64] summarised the relevant research published in the previous
10 years. It described, irrespective of quality, a total of 84 cross-sectional studies and 25 prospective
studies that had investigated the relationship between homocysteine and/or B vitamins and brain
function. Of these, 77 of the cross-sectional studies, with a total sample of more than 34,000 subjects,
demonstrated a negative relationship between cognitive deficits or dementia and the status of folate or
vitamins B12 or B6 and/or the opposite relationship with regard to homocysteine levels. Only seven
studies incorporating ~10% of the number of subjects failed to report such relationships. Similarly,
13 prospective studies incorporating more than 7000 subjects described a relationship between baseline
homocysteine and subsequent cognitive deficits measured between 2.3 and 8 years later. Similar, but
less striking negative relationships between vitamin status at the outset and subsequent cognitive
decline were evident in six of the 16 studies that assessed vitamin B12 and 10 of the 19 studies that
assessed levels of folate. It was particularly noteworthy that less than 10% of the studies incorporated
in the review included an assessment of vitamin B6, and no studies investigated the relationships
pertaining to any of the remaining five B vitamins.
Since Smith’s [64] paper, a number of meta-analyses of data from the more methodologically
rigorous, recently published studies have been conducted, although it is notable that these analyses
applied differing methodological inclusion criteria, and almost exclusively included studies involving
samples of elderly adults. These meta-analyses show a reasonably clear relationship between
homocysteine levels and dementia in cross-sectional [113] and prospective studies, with high serum
homocysteine at the study outset associated with a 35% increased chance of subsequently developing
dementia across eight studies [114] and a 50% greater chance of suffering clinically significant cognitive
decline across a further 14 studies [115]. Interestingly, at the other end of the life-span, a single study
also demonstrated a positive relationship between dietary folate intake and academic achievement in
adolescents [116].
In terms of circulating vitamin status, analysis of the data from 10 cross-sectional studies
and one prospective study demonstrated a relationship between low folate and vitamin B12 and
depression [117], and analysis of data from 10 cross-sectional and three cohort studies showed that
that folate, but not vitamin B12 was associated with cognitive impairment, typically assessed with
the Mini Mental State Exam (MMSE) [118]. This fits well with the findings of O’Leary et al. [119]
who identified 35 prospective studies but found no relationship between low serum/plasma vitamin
B12 and risk of dementia, or cognitive function. However, the authors note that the small subset of
studies that included more sensitive measures of vitamin B12 status (such as methylmalonic acid or
holotranscobalamin) demonstrated relationships in terms of dementia or cognitive function. This
conclusion was in agreement with that of Doets et al. [120] who conducted a slightly more restricted
meta-analysis. However, it contrasted with re-analysis of the data from two studies [67] that found that
whereas low vitamin B12 was associated with cognitive impairment and dementia, and low vitamin
B6 was associated with cognitive impairment, there was no relationship between brain function and
folate, homocysteine or the MTHFR C677TT polymorphism.
Of course, each of these meta-analyses included differing collections of studies, depending on
their investigational aims and inclusion/exclusion criteria, and this factor may be all important in
dictating the eventual results. As an example, Lopez da Silva et al. [121] in a comprehensive review
encompassing the relationship between a number of micronutrients and dementia, noted that only 14
out of 31 studies that they identified that had assessed folate, and only nine out of 33 studies that had
assessed vitamin B12 actually demonstrated decreased vitamin levels in sufferers from Alzheimer’s
disease. However, no studies reported the opposite relationship, and meta-analysis of the overall data
confirmed the relationships. This study was interesting in two further respects. The first was that it
included a meta-analysis of data from studies in which the dementia and control populations had
equivalent nutrition, ruling out the confounding effects of any disease related differences in overall
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diet on the results. The second was that it also illustrated the extreme bias in observational studies
towards investigations involving folate and Vitamin B12. In contrast to this voluminous body of work,
only two studies included an investigation of either thiamine or vitamin B6, and no studies assessed
the relationships between levels of the other B vitamins and any aspect of brain function.
6.2. Controlled Intervention Trials
6.2.1. Folate, Vitamin B12 and Vitamin B6
Whilst the substantial observational literature in this area suggests a consistent relationship
between aspects of brain function and folate/B12 and/or homocysteine, a huge research effort
predicated on the hypothesis that supplementation with these vitamins should decrease homocysteine
levels and thereby either improve cognitive function or attenuate cognitive decline and the risk of
dementia has generated largely equivocal results. Indeed, reviews and meta-analyses published over
more than a decade have provided scant evidence to support this hypothesis [122–127]. Two recent
extensive meta-analyses illustrate the equivocal nature of the data. In the first of these Ford and
Almeida [128] analysed the data from 19 studies involving aged participants, and found that there
was no evidence that supplementation with folic acid, alone or in combination with vitamins B12
and B6, could improve or attenuate declines in cognitive function. This finding was irrespective of
the cognitive status of participants at the outset, the study duration or size, or the background folate
status of the study populations. More recently, Clarke et al. [68] meta-analysed data from 11 studies
involving a total of 22,000 aged participants who received folic acid, with additional vitamin B12
(10 studies) and B6 (eight studies) and found no evidence of benefits either in terms of global cognitive
function or performance in specific cognitive domains, despite a drastic reduction in homocysteine
levels. However, it may be notable that this meta-analysis excluded any trials on people with cognitive
impairment or dementia and therefore did not address the question of whether these B vitamins
slowed cognitive decline.
Of course, these demonstrations of a lack of efficacy have elicited a counter-commentary noting
that the null findings may be due to a number of methodological factors, including: the study selection;
the heterogeneity or insensitivity of the cognitive tests; the good, or bad, cognitive status of the
participants at the studies’ outsets; the duration of treatment; and the pooling of data obscuring the
positive findings from more methodologically rigorous studies and those in sub-populations that are
more likely to see benefits including those with poorer vitamin status [101,129–131]. Examples of the
latter include positive findings in groups suffering high levels of homocysteine at the outset [132,133].
It has also been noted [129] that more consistent evidence exists for lower vitamin B12 status and higher
homocysteine levels being associated with decreased brain volume [134,135] and increased white
matter lesions [136] and for supplementation with homocysteine lowering B vitamins attenuating the
rate of cerebral atrophy associated with dementia and age related cognitive impairment, particularly
in those with higher homocysteine levels at the outset [137,138]. A further crumb of comfort was
also provided by a recent meta-analysis [139] of 10 studies involving supplementation with folic
acid, plus vitamin B12 (four studies) and vitamin B6 (three studies) and a single study of vitamin B12
monotherapy, and depression in sufferers of mood disorders. Whilst this analysis showed no global
benefits of supplementation on depressive symptoms across studies, the subset of three studies that
assessed relapse or prevention demonstrated significant benefits for B vitamin treatment. It may be
relevant that these were also the three studies that administered all three B vitamins.
Interestingly, the commentary surrounding the equivocal nature of the evidence in this area has
not included any reference to the predominant use of elderly participants in these studies, or whether
providing an absolute maximum of three B vitamins (folate, B6, B12), simply on the basis that these
will reduce levels of homocysteine, is a rational approach, given the inextricably inter-linked functions
of all eight B vitamins (and the potential for deficiencies/insufficiencies in any of these vitamins).
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6.2.2. Thiamine, Riboflavin, Biotin, Pantothenic Acid, Niacin
Unfortunately, there is a general dearth of controlled trial research into the effects of the remaining
B vitamins on brain function, or indeed any aspect of functioning in humans. Some supportive
evidence does exist that shows that several of this group can modulate peripheral cardiovascular
and gluco-regulatory function—and it is certainly the case that modulation of these parameters
should have an impact on brain function. For instance, administration of 1.6 mg/day of riboflavin
attenuated the hypertensive effect of the MTHFR 677TT genotype [140] and up to 4 mg/day led
to dose-related increases in the number of circulating red blood cells and the concentration of
haemoglobin [43]. Additionally, large doses (60+ ˆ RDA) of biotin, with [141,142] or without additional
chromium [143,144] have been shown to improve glycaemic control and/or insulin sensitivity in
sufferers from diabetes. Similarly, both single intravenous and chronic oral mega-doses of biotin have
been shown to improve lipid profiles in humans [144,145]. Finally, a meta-analysis of the data from
11 studies involving niacin supplementation confirmed that high doses (typically 1–4 g) either with
or without statins reduced the incidence of cardiovascular disease and coronary heart disease events,
but that this was not related to niacin’s beneficial effects on blood lipid profiles [146]. Other potential
mechanisms underlying these effects include beneficial effects on inflammatory biomarkers [147] via
modulation of NIACR1 receptors [112].
A single study has also assessed the direct effects of 50 mg (i.e., 40 ˆ RDA) of thiamine or placebo
administered for two months to 120 young females with adequate thiamine status at the study outset.
The results showed that thiamine improved mood as assessed by the Profile of Mood States, and
improved attention as evinced by faster decision times in two-choice, four-choice and eight-choice
reaction time tasks [148].
6.2.3. Multivitamins and Brain Function
Despite clear evidence that the cellular functions of B vitamins are closely inter-related, no research
to date has attempted to elucidate the effects of a full range of B vitamins with regard to any aspect of
brain function (or indeed any other function). However, a growing body of research has assessed the
effects of multi-vitamins/minerals which include a full range of B vitamins. Whilst the comparative
contributions of the B vitamins in these treatments cannot ultimately be differentiated from those of
the other vitamins and minerals in the interventions, these treatments could certainly be conceived as
providing a clearer picture of the effects of “B vitamins” as a group than the research that has focussed
on folic acid, often with additional vitamin B12 and sometimes with vitamin B6. This research can
typically also be differentiated from that summarised above on the basis that it has typically employed
samples of cognitively intact, children and non-elderly adults.
6.2.4. Acute Effects of Multivitamins
Interestingly, the orthodoxy that vitamins have to be administered for an extended period of time
in order to elicit any physiological effects is not based on any evidence that vitamins do not exert
acute effects. Comparatively few studies have assessed the acute effects of vitamins, but from those
studies that have, there is emerging evidence that vitamins have physiological and brain function
effects following a single dose. For instance, single doses of a range of single vitamins, including folic
acid (as well as vitamins C, E, A), administered at “mega-doses” of between five and 26 times the RDA
for that micronutrient, have all been shown to increase vasodilation in groups with disease-related or
experimentally induced endothelial dysfunction [149–153]. Acute administration of vitamin B6 has
also been shown to elicit increased serotonin synthesis in the primate brain [154], whilst, in a placebo
controlled, double blind, cross-over study in humans, the higher of two single doses of vitamin B6
(100 mg, 250 mg) also engendered an increase in dream salience (vividness, bizarreness, emotionality,
and color) [155].
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The direct acute effects of single doses of multi-vitamins (plus minerals) on brain function have
also been assessed in several studies. Haskell et al. [156] investigated the effects of a multivitamin/
mineral on cognitive function in children after a single dose (and after four and eight weeks) and
found that improvements in attention task performance and in a semantic memory task were evident
as early as 3 h following the first dose. Two studies have also demonstrated that a single dose of
a multi-vitamin/mineral can significantly modulate regional brain activity during a task measuring
focussed attention as measured with functional magnetic resonance spectroscopy (fMRI) [157], and
cerebro-electrical activity during an attention task as measured by electroencephalography (EEG) [158].
In the latter study EEG changes following the multi-vitamin treatment correlated with changes in task
performance. A recent study [159] also investigated the impact of two doses of multi-vitamins/minerals
that differed on the basis of their water soluble vitamin content (1 RDA and 3 RDA) on cerebral
blood-flow in the frontal cortex (using Near Infrared Spectroscopy) and overall energy expenditure
and metabolism (using Indirect Calorimetry of exhaled gas) during difficult cognitive tasks. This
study demonstrated significantly increased fat metabolism and overall energy expenditure during
cognitive task performance within 2 h of consuming the higher dose (3 RDA) of water soluble vitamins,
and increased cerebral blood-flow following the lower 1 RDA dose of vitamins.
6.2.5. Chronic Effects of Multi-Vitamins in Children
In terms of supplementation with multi-vitamins, Benton [160], reviewed the results of studies
published within the preceding decade that had assessed the effects of supplementation with
multi-vitamin/minerals on children’s intelligence (IQ). All of the treatments included a full range of
B vitamins, typically administered at much higher levels than the adult RDA. Benton noted evidence
of improved performance in 10 out of the 13 studies, with improvements exclusively restricted to
non-verbal tests of intelligence (i.e., those “fluid” intelligence tasks that do not require knowledge
or vocabulary and which could therefore be conceived as more closely reflecting the biological
functioning of the brain). Eilander et al. [161] revisited the subject with a meta-analysis that included
15 multivitamin mineral studies, 12 of which had involved administration of a full range of B vitamins,
with a further two of the remainder including folate and vitamins B12 and B6 alongside other vitamins.
They concluded that there was evidence of a “marginal increase in fluid intelligence and academic
performance in healthy schoolchildren”. Similarly, Frensham et al. [162] reviewed those studies
from developed countries that included effect sizes and identified 10 studies that showed cognitive
benefits, as opposed to four that did not. They concluded that these results show that multivitamin
supplementation may engender benefits in nonverbal intelligence and in other behavioural measures.
6.2.6. Chronic Effects of Multi-Vitamins in Adults
With regards multi-vitamins and adults, Kennedy and Haskell [28] identified 10 studies involving
chronic multi-vitamin supplementation, almost exclusively conducted in cohorts of non-elderly adults.
Across these 10 studies, all but one study reported improved psychological/cognitive functioning
following supplementation, although four studies found these effects were restricted to sub-groups
within their sample. In a subsequent meta-analysis of some of the cognitive data from 10 controlled
trials of multi-vitamins that employed several similar memory measures, Grima et al. [163] found that
multi-vitamin supplementation improved performance of some memory tasks, with too little data on
tasks assessing other cognitive domains to arrive at a conclusion. A subsequent meta-analysis of the
data from eight studies that included an assessment of the effects of multivitamins on aspects of mood
and psychological state [100] found that supplementation reduced clinical ratings of perceived stress,
mild psychiatric symptoms and anxiety. Of particular interest, the studies included in this analysis
could be subdivided into those that administered higher (4RDA) levels of B vitamins with lower levels
of other micronutrients, or lower (1RDA) levels of B vitamins with higher levels of other micronutrients.
This analysis suggested that higher B vitamins with lower levels of other micronutrients engendered
stronger effects, suggesting both a dose-response and that the efficacy of the products lay primarily
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with the B vitamin constituents. These conclusions received further support from a more recent study
that also demonstrated improved mood following four weeks of supplementation with a multivitamin
containing high levels of B vitamins [164]. Interestingly, several of the studies included in the reviews
described above also included assessments of homocysteine levels before and after treatment, and
demonstrated both that homocysteine levels were approaching levels indicating cardiovascular risk in
the studies’ healthy, non-elderly samples, and also that multivitamins normalised these levels [165]
including in a dose-related manner when 1RDA and 3RDA of B vitamins were administered [159].
In contrast to the benefits seen across a wide range of studies, a recent large study of long-term
(12 years) multivitamin supplementation in over 5000 elderly (average 71.6 years at commencement)
male retired doctors showed no cognitive effects. However, the interpretation of this study was limited
by several factors: it employed a relatively crude cognitive assessment undertaken over the telephone;
the participants were elderly, well-nourished, and highly educated; only one eighth of the sample
received a true placebo, with three quarters of the multivitamin placebo group receiving combinations
of vitamins A, C and E; and finally, the B vitamins were administered at approximately 1RDA, with
the exception of vitamins B12 (10 ˆ RDA) and B6 (2.5 ˆ RDA). Finally, and most interestingly, whilst
this study was explicitly investigating the potential for vitamins to attenuate cognitive decline in the
elderly, there was no evidence of declining performance over the 12 years of the study in either the
placebo or multivitamin groups [166].
It is also worth noting that a number of other recent studies have also demonstrated improved
psychological or cognitive functioning following products containing multi-vitamins [167–171],
although the interpretation of these studies with regards their vitamin content is limited by
the inclusion of multiple herbal extracts at potentially psychoactive levels in the formulations.
However, it may be relevant that one of these studies demonstrated a correlation between improved
performance in a focussed attention (Stroop) task and changes in blood levels of vitamin B6 following
supplementation [170].
7. Summary and Conclusions
The B vitamins represent a group of eight essential dietary micronutrients that work closely
in concert at a cellular level and which are absolutely essential for every aspect of brain function.
As water soluble nutrients, they are generally safe at levels of consumption well in excess of the
recommended minimum consumption levels (possibly with the exception of folic acid, see Section 5).
Indeed, bioavailability and functional data suggest that consumption of most B vitamins at levels well
above dietary recommendations would be warranted.
Whilst adequate levels of all of the B vitamins should be obtainable from a healthy diet, evidence
suggests that large sub-sections of the populations of developed countries are suffering deficiencies or
marginal deficiencies in one or more B vitamins that will predispose them to a number of negative
health consequences, including less than optimal brain function. Both epidemiological and controlled
intervention trial research, driven by the predominant “homocysteine hypothesis”, have overly
concentrated on the relationships with brain function, and the effects of supplementation on brain
function of a narrow group of three homocysteine lowering B vitamins—folate and vitamin B12 and,
to a lesser extent, vitamin B6. The potential roles and effects on brain function of the remaining five
inter-related B vitamins have been largely ignored. As a consequence, consistent evidence suggests
that biochemical levels of this narrow band of three vitamins, and related levels of the amino-acid
homocysteine, correlate positively and negatively with brain function, respectively. However, the
evidence that supplementation with one or more of these three homocysteine lowering vitamins in
isolation improves brain function is entirely equivocal.
The lack of demonstrable efficacy seen in multiple meta-analyses of supplementation trials
involving this small sub-group of homocysteine lowering B vitamins has often prompted a counter
commentary that persists with the notion that the underlying homocysteine hypothesis is likely to be
correct, suggesting rather that the methodology or focus of the individual studies or meta-analyses
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are incorrect, and that future research should be directed towards sub-groups of the population more
likely to benefit, in trials that employ more sensitive measures (e.g., [131]). This may prove a fruitful
approach, but given the inter-related cellular functions of the B vitamins, a more rational approach to
research must be to investigate the effects of supplementation with the full range of B vitamins, at doses
well in excess of the current governmental RDAs. There is no compelling argument for restricting this
research either to a small sub-group of three B vitamins or to the elderly groups of subjects usually
employed in these trials. Certainly, the smaller body of research investigating multivitamins, which
has largely been undertaken in healthy children and non-elderly adults, suggests significant benefits
to brain function following supplementation with multivitamin products containing a full range of
B vitamins at levels well in excess of their RDAs.
It is also notable that treatments containing all of the B vitamins will inevitably reduce
homocysteine (see [159,165]), and indeed, given the direct contribution of both niacin and riboflavin
to the folate/methionine cycles, they should theoretically be more effective than small sub-groups of
B vitamins in this regard. It is therefore difficult to conceive of any potential downsides to undertaking
research with the full range of B vitamins. Of course, the luxury of being able to attribute any benefits
to a single molecule and/or a single mechanism will be lost, but given the equivocal nature of the
large body of evidence to date with regards to the homocysteine hypothesis, this loss would appear
supportable, if not inevitable.
Naturally, the B vitamins, as a group and individually, also work intricately in concert with other
vitamins, minerals and micronutrients. Whilst this topic is outside of the scope of the current review,
it is noteworthy that a concerted research effort aimed at elucidating the full range of micronutrient
interactions is warranted. For the moment, the foregoing suggests that research should, at a minimum,
be redirected towards elucidating the potential benefits for brain function of both the acute and chronic
administration of a full range of B vitamins rather than concentrating solely on the chronic effects of
a small sub-group of three vitamins.
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The following abbreviations are used in this manuscript:
AADC, aromatic L-amino acid decarboxylase
AAAH, aromatic amino acid hydroxylases
ATP, adenosine triphosphate
BCKDC, branched-chain α-ketoacid dehydrogenase complex
BH2, dihydrobiopterin
BH4, tetrahydrobiopterin
CBS, cystathionine beta synthase
CGL, cystathionine gamma-lyase
CoA, coenzyme A
CS, citrate synthase
DHFR, dihydrofolate reductase
dTMP, thymidine monophosphate
dUMP, deoxyuridine monophosphate
EEG, electroencephalography
EGRAC, erythrocyte glutathione reductase activation test
FAD/FADH2, flavin adenine dinucleotide (oxidised/reduced)
fMRI, functional magnetic resonance imaging
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GABA, gamma-aminobutyric acid
GSSG, glutathione disulphide
IDH, isocitrate dehydrogenase
MAT, methionine adenosyltransferase
MDH, malate dehydrogenase
MCM, methylmalonyl-CoA mutase
MMSE, Mini Mental State Exam
MS, methionine synthase
MTHFR, methyltetrahydrofolate reductase
MTRR, methionine synthase reductase
NAD, nicotinamide adenine dinucleotide (+/H = oxidised/reduced)
NIACR, Niacin receptor
NOS, nitric oxide synthase
OGDH, α-ketoglutarate dehydrogenase
PCC, propionyl-CoA Carboxylase
PC, pyruvate carboxylase
PD, pyruvate dehydrogenase
RDA, Recommended Daily Allowance
RDI, Recommended Daily Intake
SAH, S-adenosylhomocysteine
SAHH, S-adenosylhomocysteine hydrolase
SAM, S-adenosyl methionine
SCS, succinyl-CoA synthetase
SH, serine hydroxymethyltransferase
SQR, succinate-coenzyme Q reductase
THF, tetrahydrofolate
TS, thymidylate synthase
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